Eos Energy stock falls after Fuzzy Panda issues short report
Director Patrick D. Spangler of OptimizeRx Corp (NASDAQ:OPRX) sold 11,120 shares of common stock on August 28, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at prices ranging from $17.47 to $18.43, for a total value of $194,488. The transaction comes as OptimizeRx shares trade near their 52-week high of $19.25, having delivered an impressive 324% return over the past six months. According to InvestingPro analysis, the company maintains a GREAT financial health score, with analysts setting price targets ranging from $11 to $27.
Following the transaction, Spangler directly owns 44,215 shares of OptimizeRx Corp. Want deeper insights into insider transactions and comprehensive analysis? InvestingPro offers exclusive access to detailed insider trading patterns and 13 additional key insights about OPRX’s valuation and growth prospects.
In other recent news, OptimizeRx Corp. reported impressive second-quarter financial results, with revenue reaching $29.2 million, marking a 55% increase from the previous year. This figure significantly surpassed analyst estimates, including JMP Securities’ projection of $22.2 million and the consensus expectation of $22.3 million. The company’s earnings per share (EPS) also surprised analysts, coming in at $0.24 compared to the forecasted $0.02, a remarkable 1100% increase. Following these strong earnings, JMP Securities raised its price target for OptimizeRx from $14 to $20, maintaining a Market Outperform rating. Additionally, OptimizeRx has announced a series of leadership changes as part of its "Rule of 40" strategy to drive growth and profitability over the next few years. Ed Stelmakh has been appointed as Chief Financial & Strategic Officer, expanding his role to include broader corporate strategy alongside financial leadership. These developments reflect the company’s ongoing efforts to strengthen its market position and enhance shareholder value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.